Nov 20 (Reuters) - Merck said on Friday that its experimental cancer drug helped patients with advanced stomach and esophageal cancers live longer than standard treatment options in a late-stage trial. Here are some details: • The trial compared the ...
The clinical trial compared Merck's drug sacituzumab tirumotecan, also known as sac-TMT, with doctor-chosen chemotherapy, such as trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel.